Sarah Timsit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarah Timsit has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Maud Salmona
Hôpital Saint-Louis
3 shared publications - Jérôme LeGoff
Virology Department AP‐HP, Hôpital Saint Louis Paris France
2 shared publications A. Alanio
Laboratoire de Parasitologie - Mycologie, Hôpital Saint-Louis AP-HP, F-75018, Paris, France; Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, Groupe de recherche Mycologie Translationnelle, Département de Mycologie, F-75015 Paris, France
1 shared publication- Audrey Mansuet-Lupo
Service d'anatomie pathologique, hôpital Cochin, 27, rue du faubourg Saint-Jacques, 75014 Paris, France
1 shared publication - Aurélien Aubry
Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, Université de Picardie Jules Verne, Chemin du Thil, 80025 Amiens, France
1 shared publication Benjamin Besse
Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0167925
Influence of iron uptake systems on cefiderocol activity in Escherichia coli : At the crossroads of antibiotic resistance and virulence
Cefiderocol (FDC) is a new siderophore-conjugated cephalosporin that enters the periplasm via iron transport systems. However, the specific contribution of individual iron uptake pathways to FDC activity remains unclear. We investigated the role of 13 iron acquisition systems using several Escherichia coli strain collections. FDC MICs were determined in iron-depleted and iron-supplemented media for E. coli mutants (Keio and pathogenic island [PAI]-deleted collections) and for no-acquired β-lactamase or TEM (NoBL/TEM- Ec ) and NDM-producing E. coli (NDM- Ec ) clinical isolates. Prevalence of iron uptake genes was assessed in these isolates, and fec operon prevalence and genomic location were investigated in E. coli genomes from EnteroBase and RefSeq databases. Compared to K-12 and 536 reference E. coli , only Δ cirA and Δ fiu (enterobactin system) showed increased FDC MICs (8- and 3-fold, respectively), while Δ fecA and Δ fecB had lower MICs (3-fold decrease). The fec operon, a known extraintestinal virulence factor, was significantly more prevalent in isolates with FDC MICs above median than below (96% vs. 33% in NoBL/TEM- Ec ; 100% vs. 0% in NDM- Ec ). According to EUCAST breakpoints, 63.6% of fec -positive NDM- Ec were resistant to FDC, whereas none of the fec -negative were. The fec operon was found in 46.5% of E. coli genomes, including virulent clones (ST131, 77%) and was mostly chromosome-borne (99%). Plasmid-borne fec closely resembled that of Enterobacter hormaechei or Klebsiella pneumoniae , suggesting interspecies transfer. Our findings highlight the role of Fec in reducing FDC susceptibility and promoting resistance in NDM-producing E. coli . They challenge the virulence-resistance trade-off demonstrating the “liaisons dangereuses” between iron and antibiotics.
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0167925
Open AccessInfluence of iron uptake systems on cefiderocol activity in Escherichia coli : At the crossroads of antibiotic resistance and virulence
Cefiderocol (FDC) is a new siderophore-conjugated cephalosporin that enters the periplasm via iron transport systems. However, the specific contribution of individual iron uptake pathways to FDC activity remains unclear. We investigated the role of 13 iron acquisition systems using several Escherichia coli strain collections. FDC MICs were determined in iron-depleted and iron-supplemented media for E. coli mutants (Keio and pathogenic island [PAI]-deleted collections) and for no-acquired β-lactamase or TEM (NoBL/TEM- Ec ) and NDM-producing E. coli (NDM- Ec ) clinical isolates. Prevalence of iron uptake genes was assessed in these isolates, and fec operon prevalence and genomic location were investigated in E. coli genomes from EnteroBase and RefSeq databases. Compared to K-12 and 536 reference E. coli , only Δ cirA and Δ fiu (enterobactin system) showed increased FDC MICs (8- and 3-fold, respectively), while Δ fecA and Δ fecB had lower MICs (3-fold decrease). The fec operon, a known extraintestinal virulence factor, was significantly more prevalent in isolates with FDC MICs above median than below (96% vs. 33% in NoBL/TEM- Ec ; 100% vs. 0% in NDM- Ec ). According to EUCAST breakpoints, 63.6% of fec -positive NDM- Ec were resistant to FDC, whereas none of the fec -negative were. The fec operon was found in 46.5% of E. coli genomes, including virulent clones (ST131, 77%) and was mostly chromosome-borne (99%). Plasmid-borne fec closely resembled that of Enterobacter hormaechei or Klebsiella pneumoniae , suggesting interspecies transfer. Our findings highlight the role of Fec in reducing FDC susceptibility and promoting resistance in NDM-producing E. coli . They challenge the virulence-resistance trade-off demonstrating the “liaisons dangereuses” between iron and antibiotics.
- Open Access
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0347025
Evaluation of the STANDARD M10 and Xpert C. difficile assays for the detection of toxigenic Clostridioides difficile in stools
This study aims to compare the sensitivity and specificity of two Nucleic Acid Amplification Tests (NAATs), the STANDARD M10 Clostridioides difficile (M10) and the Xpert C. difficile (Xpert) assays, for the detection of toxigenic C. difficile strains in stools. This prospective study included fresh diarrheal stools. Following routine testing by the C. difficile Quik Chek Complete enzyme immunoassay (EIA), M10 and Xpert were tested in parallel alongside toxigenic culture (gold standard) on selective chromogenic medium (ChromId C. difficile ). The M10 and Xpert assays were performed by independent technicians. We also compared the results of the M10 assay from 10 native stools and fecal swab paired samples. A total of 541 stool samples were included. The toxigenic culture was positive for 60 stool specimens (11.0%), including 32 free toxin-positive stools. Both M10 and Xpert demonstrated comparable sensitivity (100%) and specificity (97.5%). The tcdB cycle threshold (Ct) values obtained with the M10 and Xpert assays were highly correlated (Pearson correlation coefficient: 0.909, P < 0.001). The median tcdB Ct values for toxin EIA-positive/NAAT-positive specimens were significantly lower than those for toxin EIA-negative/NAAT-positive specimens in both M10 (25.50 vs 32.39) and Xpert assays (23.70 vs 31.15) ( P < 0.001). Receiver operating characteristic curve analysis assessing the ability of Ct values to predict the detection of free toxins exhibited an area under the curve of 0.875 for M10 and 0.862 for Xpert. The use of 400 µL of fecal swab transport medium yielded Ct values closer than 100 or 200 µL to those from native stools. The M10 C. difficile assay displays high sensitivity and specificity and is comparable to the Xpert assay. IMPORTANCE: Our study evaluated the performances of a new NAAT assay (STANDARD M10 Clostridioides difficile assay) for detecting toxigenic C. difficile in stool specimens and compared the results to the Xpert C. difficile assay, a widely used assay in clinical laboratories. This prospective study was conducted on a very large collection of 541 diarrheal fresh stool samples, and all C. difficile isolates were characterized by PCR-ribotyping. As of today, there are limited data regarding the performances of the STANDARD M10 C. difficile assay.
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0347025
Open AccessEvaluation of the STANDARD M10 and Xpert C. difficile assays for the detection of toxigenic Clostridioides difficile in stools
This study aims to compare the sensitivity and specificity of two Nucleic Acid Amplification Tests (NAATs), the STANDARD M10 Clostridioides difficile (M10) and the Xpert C. difficile (Xpert) assays, for the detection of toxigenic C. difficile strains in stools. This prospective study included fresh diarrheal stools. Following routine testing by the C. difficile Quik Chek Complete enzyme immunoassay (EIA), M10 and Xpert were tested in parallel alongside toxigenic culture (gold standard) on selective chromogenic medium (ChromId C. difficile ). The M10 and Xpert assays were performed by independent technicians. We also compared the results of the M10 assay from 10 native stools and fecal swab paired samples. A total of 541 stool samples were included. The toxigenic culture was positive for 60 stool specimens (11.0%), including 32 free toxin-positive stools. Both M10 and Xpert demonstrated comparable sensitivity (100%) and specificity (97.5%). The tcdB cycle threshold (Ct) values obtained with the M10 and Xpert assays were highly correlated (Pearson correlation coefficient: 0.909, P < 0.001). The median tcdB Ct values for toxin EIA-positive/NAAT-positive specimens were significantly lower than those for toxin EIA-negative/NAAT-positive specimens in both M10 (25.50 vs 32.39) and Xpert assays (23.70 vs 31.15) ( P < 0.001). Receiver operating characteristic curve analysis assessing the ability of Ct values to predict the detection of free toxins exhibited an area under the curve of 0.875 for M10 and 0.862 for Xpert. The use of 400 µL of fecal swab transport medium yielded Ct values closer than 100 or 200 µL to those from native stools. The M10 C. difficile assay displays high sensitivity and specificity and is comparable to the Xpert assay. IMPORTANCE: Our study evaluated the performances of a new NAAT assay (STANDARD M10 Clostridioides difficile assay) for detecting toxigenic C. difficile in stool specimens and compared the results to the Xpert C. difficile assay, a widely used assay in clinical laboratories. This prospective study was conducted on a very large collection of 541 diarrheal fresh stool samples, and all C. difficile isolates were characterized by PCR-ribotyping. As of today, there are limited data regarding the performances of the STANDARD M10 C. difficile assay.
- 27 May 2026
- Published by Elsevier in Journal of Hospital Infection
- Vol. 174, 479-480
Re: understanding the epidemiology of Candidozyma auris: a case–control study at an acute hospital in London, UK, by Okeke et al
- 27 May 2026
- Published by Elsevier in Journal of Hospital Infection
- Vol. 174, 479-480
Re: understanding the epidemiology of Candidozyma auris: a case–control study at an acute hospital in London, UK, by Okeke et al
- Open Access
- 22 May 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (5) , e70411
Clinical and Epidemiological Insights into a Parainfluenza Virus Type 3 Outbreak in Multiple Myeloma Patients
Human parainfluenza virus type 3 (HPIV‐3) can be responsible for mild to severe respiratory infections and hospital epidemics. We investigated an outbreak in a hematology unit. Respiratory viruses were screened using multiplex PCR. HPIV‐3 quantification and whole‐genome sequencing were performed on HPIV‐3 positive respiratory samples. Clinical characteristics, infection progression, incidence rates of respiratory viruses within the hospital and detection of respiratory viruses were documented, along with the reinforcement of infection prevention and control (IPC) measures implemented. Between November 2022, and January 2023, HPIV‐3 was identified in 20 of 113 hematology patients (17.7%), of whom 80% had multiple myeloma. A majority of HPIV‐3‐positive patients developed pneumonia (60%), and mortality was notably higher (35%) compared to patients who were negative (3%, p < 0.0001). Respiratory HPIV‐3 viral loads were similar between patients with and without pneumonia. In parallel, HPIV‐3 incidence in the hospital overall was lower than in the hematology unit (p < 0.0001). Air virus screening showed the detection of HPIV‐3 in the air in different areas, and whole‐genome sequencing confirmed the circulation of a single HPIV‐3 strain. Strengthened IPC measures were associated with the containment of the outbreak. HPIV‐3 has high epidemic potential in patients with multiple myeloma and causes severe infections. Our findings highlight the need for routine HPIV‐3 testing in hematology units.
- 22 May 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (5) , e70411
Open AccessClinical and Epidemiological Insights into a Parainfluenza Virus Type 3 Outbreak in Multiple Myeloma Patients
Human parainfluenza virus type 3 (HPIV‐3) can be responsible for mild to severe respiratory infections and hospital epidemics. We investigated an outbreak in a hematology unit. Respiratory viruses were screened using multiplex PCR. HPIV‐3 quantification and whole‐genome sequencing were performed on HPIV‐3 positive respiratory samples. Clinical characteristics, infection progression, incidence rates of respiratory viruses within the hospital and detection of respiratory viruses were documented, along with the reinforcement of infection prevention and control (IPC) measures implemented. Between November 2022, and January 2023, HPIV‐3 was identified in 20 of 113 hematology patients (17.7%), of whom 80% had multiple myeloma. A majority of HPIV‐3‐positive patients developed pneumonia (60%), and mortality was notably higher (35%) compared to patients who were negative (3%, p < 0.0001). Respiratory HPIV‐3 viral loads were similar between patients with and without pneumonia. In parallel, HPIV‐3 incidence in the hospital overall was lower than in the hematology unit (p < 0.0001). Air virus screening showed the detection of HPIV‐3 in the air in different areas, and whole‐genome sequencing confirmed the circulation of a single HPIV‐3 strain. Strengthened IPC measures were associated with the containment of the outbreak. HPIV‐3 has high epidemic potential in patients with multiple myeloma and causes severe infections. Our findings highlight the need for routine HPIV‐3 testing in hematology units.
- 25 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Investigating Nosocomial BK Polyomavirus Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Challenges and Prospects
Background: The modes of transmission of BK polyomavirus (BKPyV) remain incompletely understood. BKPyV infections can lead to hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT). Hospitalization in a pediatric hematology unit may represent initial exposure to BKPyV due to the high rate of viral shedding among hematology patients. This study explores the potential for nosocomial transmission of BKPyV within a hematology department. Methods: Epidemiologic investigation and BKPyV genome phylogenetic analyses were conducted among individuals with BKPyV DNAuria and/or DNAemia over a 3-year period in a pediatric hematology unit. Results: From November 2019 to December 2022, BKPyV DNA was detected in the urine or plasma of 34 of 173 children following HSCT. An unusually high prevalence of genotype Ia BKPyV was observed in 2021, suggesting possible patient-to-patient transmission. However, despite closely related sequences, they clustered with several GenBank entries, complicating phylogenetic linkage determination. Genetic signature analysis also did not link these sequences to specific patient clinical profiles. Discussion: This study highlights the complexity of establishing nosocomial transmission of BKPyV, even with viral sequence analyses. Future prospective studies should include noncoding control region analysis, serological data, and environmental factors to enhance understanding of BKPyV transmission routes.
- 25 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Investigating Nosocomial BK Polyomavirus Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Challenges and Prospects
Background: The modes of transmission of BK polyomavirus (BKPyV) remain incompletely understood. BKPyV infections can lead to hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT). Hospitalization in a pediatric hematology unit may represent initial exposure to BKPyV due to the high rate of viral shedding among hematology patients. This study explores the potential for nosocomial transmission of BKPyV within a hematology department. Methods: Epidemiologic investigation and BKPyV genome phylogenetic analyses were conducted among individuals with BKPyV DNAuria and/or DNAemia over a 3-year period in a pediatric hematology unit. Results: From November 2019 to December 2022, BKPyV DNA was detected in the urine or plasma of 34 of 173 children following HSCT. An unusually high prevalence of genotype Ia BKPyV was observed in 2021, suggesting possible patient-to-patient transmission. However, despite closely related sequences, they clustered with several GenBank entries, complicating phylogenetic linkage determination. Genetic signature analysis also did not link these sequences to specific patient clinical profiles. Discussion: This study highlights the complexity of establishing nosocomial transmission of BKPyV, even with viral sequence analyses. Future prospective studies should include noncoding control region analysis, serological data, and environmental factors to enhance understanding of BKPyV transmission routes.
- 13 December 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (2) , 104844
The clinical and epidemiological impacts of whole genomic sequencing on bacterial and virological agents
- 13 December 2023
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (2) , 104844
The clinical and epidemiological impacts of whole genomic sequencing on bacterial and virological agents